Hyperliquid Strategies (NASDAQ:PURR) Announces Quarterly Earnings Results
by Teresa Graham · The Cerbat GemHyperliquid Strategies (NASDAQ:PURR – Get Free Report) posted its earnings results on Thursday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.
Here are the key takeaways from Hyperliquid Strategies’ conference call:
- The company holds roughly 18.8–20M HYPE tokens and reported $202.4M of treasury strategy income in Q3 (driven by a $198.4M unrealized HYPE gain), while staking all tokens and earning $2.6M in staking revenue.
- HIP-3 (real‑world asset perps) has rapidly gained traction—five of Hyperliquid’s top 10 trading pairs are real‑world assets and an oil contract hit $710M in 24‑hour volume, attracting TradFi interest.
- Hyperliquid will launch its own validator on May 11 in partnership with Unit/Trade XYZ, intended to deepen ecosystem alignment and create new revenue streams for the company.
- HIP‑4 (outcome/prediction markets) plus Builder Codes are live as proofs‑of‑concept, enabling permissionless third‑party deployers and opening addressable markets including options, insurance and pre‑IPO trading.
- The company spent about $160M acquiring HYPE, lowering cash to $113.1M, reported a nine‑month net loss of $165.4M (including a one‑time IPR&D write‑off), and carries a sizable deferred tax liability that would crystallize if tokens were sold.
Hyperliquid Strategies Price Performance
Shares of NASDAQ:PURR traded down $0.36 during trading on Thursday, reaching $6.56. The company had a trading volume of 7,939,609 shares, compared to its average volume of 4,643,935. The company has a fifty day moving average price of $5.53. The stock has a market cap of $812.98 million, a PE ratio of -0.71 and a beta of 1.44. Hyperliquid Strategies has a 12 month low of $3.01 and a 12 month high of $7.09.
Hedge Funds Weigh In On Hyperliquid Strategies
A number of institutional investors have recently made changes to their positions in PURR. Boothbay Fund Management LLC bought a new position in shares of Hyperliquid Strategies in the 4th quarter worth $40,000. XTX Topco Ltd bought a new position in shares of Hyperliquid Strategies in the 4th quarter worth $48,000. Squarepoint Ops LLC bought a new position in shares of Hyperliquid Strategies in the 4th quarter worth $73,000. Millennium Management LLC bought a new position in shares of Hyperliquid Strategies in the 4th quarter worth $87,000. Finally, Ikarian Capital LLC bought a new position in shares of Hyperliquid Strategies in the 4th quarter worth $107,000. Institutional investors own 9.45% of the company’s stock.
Analysts Set New Price Targets
PURR has been the topic of several recent analyst reports. Chardan Capital increased their target price on shares of Hyperliquid Strategies from $8.15 to $8.45 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Wall Street Zen upgraded shares of Hyperliquid Strategies to a “hold” rating in a research note on Saturday, February 21st. Cantor Fitzgerald upgraded shares of Hyperliquid Strategies to a “strong-buy” rating in a research note on Thursday, April 9th. Weiss Ratings assumed coverage on shares of Hyperliquid Strategies in a research note on Monday, March 2nd. They issued a “sell (e)” rating on the stock. Finally, Maxim Group assumed coverage on shares of Hyperliquid Strategies in a report on Friday, April 24th. They issued a “buy” rating and a $10.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.15.
Check Out Our Latest Stock Report on PURR
About Hyperliquid Strategies
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc, is based in NEW YORK.